15.05.2013 Views

ALINORM 03/26/1 - codex - BSN

ALINORM 03/26/1 - codex - BSN

ALINORM 03/26/1 - codex - BSN

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

20 REP12/CAC<br />

113. The result of the secret ballot on Vote 2 was:<br />

Ballots papers deposited: 143<br />

Defective ballots: 0<br />

Abstentions: 7<br />

Votes cast: 136<br />

Majority required: 69<br />

Votes in favour: 69<br />

Votes against: 67<br />

Result: Proposal adopted; the Commission adopted the MRLs for ractopamine<br />

in cattle and pig tissues, i.e., muscle, liver, kidney and fat.<br />

114. The Delegation of China expressed their disappointment that the Commission did not resolve the issue<br />

by consensus. They reiterated their position against the adoption of the MRLs for ractopamine and expressed<br />

their reservation.<br />

115. The Delegation of Norway strongly opposed the adoption of the draft MRLs, as they still had human<br />

health concerns and because of the non-therapeutic use of ractopamine. The Delegation was concerned<br />

because the draft MRLs had been pushed forward when many members had asked for a consensus-based<br />

decision and the MRLs had been adopted despite a clear lack of consensus. They noted that without a global<br />

agreement the MRLs would not be applicable worldwide.<br />

116. The Delegation of the European Union stated that it was strongly opposed to the adoption of the MRLs<br />

for ractopamine in pigs and cattle as there were outstanding concerns regarding its safety assessment. The<br />

European Union's risk assessment body, the European Food Safety Authority, concluded that there is<br />

insufficient data upon which to make a proposal for MRLs for ractopamine and that possible risks to human<br />

health had not been sufficiently ruled out. As ractopamine is solely used for the purpose of growth promotion,<br />

the European Union could not support an international standard that endorsed, or worse still, encouraged its<br />

use.<br />

117. The European Union, therefore, recorded its strong opposition to the adoption of the MRLs for<br />

ractopamine by the Commission. The Delegation also underlined that, given its outstanding safety concerns,<br />

the European Union's current legislation would remain in place. The Delegation was also of the view that the<br />

Commission should take time to reflect upon what to do about standards held at Step 8. There had been a<br />

number of attempts to seriously consider what to do in these cases, and yet, for a variety of reasons, these<br />

attempts had been thwarted and no real progress had been possible. The Delegation emphasised that it was in<br />

the best interest of the Commission to seriously reflect on this matter.<br />

118. The European Union stressed that Codex, as a consensus-based organisation had not been well served<br />

by what had happened at this session of the Commission. The membership of Codex, had spoken out, loud<br />

and clear on various occasions, expressing their clear preference for matters to be decided in Codex on the<br />

basis of consensus. By conducting a vote at this session, this preference had been blatantly ignored. The<br />

European Union deplored not only the fact that an international standard had been set for ractopamine but<br />

also deplored, in the strongest of terms, the manner in which this conclusion was reached. For the above<br />

reason, the European Union recorded their strong opposition to the adoption of the MRLs for ractopamine.<br />

119. The Delegation of the United States of America stated that they were pleased with the adoption of the<br />

MRLs for ractopamine, but they took no pleasure in the fact that this had been a difficult decision. The<br />

Delegation thanked the Chairpersons of the Commission and the CCRVDF for all efforts made over the years<br />

to try to achieve consensus and to use all the tools in the Procedural Manual to find a way forward. The<br />

Delegation expressed the wish that adopting standards in Codex through a vote should remain a rare<br />

exception to the general rule of consensus. They looked forward to working with members to ensure that<br />

Codex remains willing and able to make science-based and timely decisions on food safety.<br />

120. The following delegations expressed their reservation to the adoption of the MRLs for ractopamine<br />

and made the following comments:<br />

- Kenya: was of the view that not all safety concerns had been addressed and that with such sustained<br />

opposition no international standard should be set.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!